Cargando…
An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations
The natural product goldenseal is a clinical inhibitor of CYP3A activity, as evidenced by a 40%–60% increase in midazolam area under the plasma concentration versus time curve (AUC) after coadministration with goldenseal. The predominant goldenseal alkaloids berberine and (−)-β-hydrastine were previ...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658920/ https://www.ncbi.nlm.nih.gov/pubmed/37541764 http://dx.doi.org/10.1124/jpet.123.001681 |